Venous thromboembolism (VTE) is the third most common cause of vascular mortality
worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

The risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) associated
with immune checkpoint inhibitors is currently unclear. Our aim was to quantify the risk of …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

Patients with cancer are characterized by a dysregulation of the hemostatic system and
systemic hypercoagulability. Different components of the hemostatic system are involved in …

Venous thromboembolism (VTE) is a clinical disease that includes deep vein thrombosis
and pulmonary embolism. Amongst its underlying risk factors, cancer is of great importance …

Abstract Background The Khorana score (KS) clinical algorithm is used to predict VTE risk in
cancer patients. The study objective was to evaluate VTE and survival rates among patients …

Cancer-associated venous thromboembolism (VTE) has major consequences for patients,
including morbidity and risk of mortality. However, there is substantial variation in risk …

Background Venous thromboembolism (VTE) is a frequent complication of cancer. Elevated
D‐dimer is associated with an increased risk of cancer‐associated VTE. Whether changes in …